Primary risk
Primary risk: cardiovascular strain
Combinations significantly increase cardiac risk.
SuspectedLaden…
Translation in progress
This section is currently being translated. Content will be available soon.
View German version →Newly emerging RC with stimulant-like profile — cardiovascular risk, no validated human data.
Evidence confidence
Critical risk signals
Combinations significantly increase cardiac risk.
SuspectedFurther risks (class-based)
Combinations significantly increase cardiac risk.
Synapedia is actively monitoring this substance. Data is updated as new signals emerge.
Scientific interpretation
Why is this substance flagged?
This substance is flagged because structural-chemical features indicate a stimulant-like profile. Cardiovascular strain is class-documented. No substance-specific human data are available.
No validated human data exist for this substance. The risk profile is extrapolated from class characteristics. Structural-chemical features may hint at possible mechanisms but do not substitute for substance-specific preclinical or clinical data.
Class-based — no substance-specific primary literature
Where does this assessment come from?
Known — structure-based
Derived from stimulant class profile and structural-chemical features.
Suspected — class-based
Extrapolated from known stimulant profile: catecholamine release, cardiovascular strain.
Unknown — no human data
Substance-specific data on pharmacokinetics, dose range and long-term effects are entirely absent.
Deep-dive intelligence
Community reports and forum discussions exist for this substance. Synapedia treats these as monitoring signals, not verified human data. Reports may be confounded by tolerance, polydrug use and unverified product identities.
Community reports are uncontrolled. It often remains unclear:
Synapedia documents community signals but does not derive dose ranges or equivalences from them.
Receptor Targets
Mechanism of Action
3-FPO acts through the following pharmacological mechanisms:
Designations
Receptor Profile
Der Noradrenalintransporter (NET) ist ein Monoamintransporter, der Noradrenalin aus dem synaptischen Spalt zurücktransportiert. Er wird von verschiedenen Stimulanzien und Antidepressiva beeinflusst.
Der Dopamintransporter (DAT) ist ein Natrium-abhängiger Monoamintransporter, der Dopamin aus dem synaptischen Spalt entfernt. Er ist ein zentrales Ziel von Stimulanzien und spielt eine Schlüsselrolle im Belohnungssystem.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class.
Synapedia Evidence
Effects & Pharmacology — Translation in progress
This section is being translated. Content is available in German.
View in German →Risks & Harm Reduction — Translation in progress
This section is being translated. Content is available in German.
View in German →The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
Help improve the evidence picture — for emerging RCs, reviewed community signals are especially valuable.
For emerging RCs, reports are reviewed especially cautiously. Claims about identity, strength, effects, and duration remain unverified.
The signal hub collects approved risk signals, experience reports and source leads by relevance.